# Nasal Dexmedetomidine Versus Systemic Infusion Dexmedetomidine in Reducing Intraoperative Opioid Consumption in Nasal Endoscopic Surgeries

> **NCT07012213** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Cairo University** · enrollment: 50 (estimated)

## Conditions studied

- Functional Endoscopic Sinus Surgery (FESS)

## Interventions

- **DRUG:** Patients in group A received .5 g/kg/h dexmedetomidine infusion after general anesthesia, in group B received 1 ml (100 mic) dexmedetomidine intranasal spray before induction.

## Key facts

- **NCT ID:** NCT07012213
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2025-11-15
- **Final completion:** 2025-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07012213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07012213, "Nasal Dexmedetomidine Versus Systemic Infusion Dexmedetomidine in Reducing Intraoperative Opioid Consumption in Nasal Endoscopic Surgeries". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07012213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*